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Introduction: PEGylated liposomes are widely used and studied as carriers for chemothera-
peutics. While pharmacokinetics of the encapsulated drug is drastically altered resulting in 
favorable circulation time, improved tumor accumulation, and better manageable or reduced 
side effects, therapeutic efficacy has been disappointing. Major drawbacks are a failure to reach 
the tumor cell, limited penetration depth, and impaired uptake by tumor cells.
Materials and methods: Here, we study the implication of HIV-1 transactivator of transcrip-
tion (TAT)-derived peptides inserted on PEGylated liposomal doxorubicin (PLD) and followed 
in vitro and in vivo fate. PLDs were installed with 25–400 TAT peptides per liposome without 
an effect on PLD stability.
Results: While TAT peptides facilitate active endocytosis of the carriers, we observed that these 
peptides did not promote endosomal escape or enhanced intracellular availability of doxorubicin. 
Interestingly, incorporation of TAT peptides did not change pharmacokinetics or biodistribu-
tion, which we found to result from a dysopsonization of the TAT-modified liposomes by serum 
proteins. A protein corona (PC) on TAT peptide-modified PLDs shields the active moieties and 
effectively reduces clearance of the TAT peptide containing nanoparticles. However, intratumoral 
activity was influenced by the number of TAT peptides present. The best antitumor efficacy was 
observed with a TAT peptide density of 100, while lower amounts showed results comparable 
to unmodified PLDs. At 200 TAT peptides, the preparation appeared to be least effective, which 
likely results from augmented interaction with tumor cells directly upon extravasation.
Conclusion: We conclude that by optimizing TAT-modified PLDs, the occurring PC balances 
pharmacokinetics and tumor penetration through interference with avidity.
Keywords: PEGylated liposomal doxorubicin, TAT peptide, ligand-modified liposomes, protein 
corona, dysopsonization
Introduction
New agents, molecules, and therapies for cancer are being developed with mixed 
success. However, quite a few classic compounds, with profound in vitro proven 
antitumor activity, are available but cannot be used optimally in patients. Poor water 
solubility, poor pharmacokinetics, and severe dose-limiting side effects hinder their 
usability in patients and adversely affect therapeutic outcome. Nanomedicines are 
employed to improve solubility, tailor release rates, and improve pharmacokinetics 
of the cytotoxic agents, while minimizing side effects.1,2 Doxil®/Caelyx® (PEGylated 
liposomal doxorubicin [PLD, Janssen Pharmaceuticals NV, Beerse, Belgium]) was 
therefore the first US FDA-approved nano-device.3–5
correspondence: Timo lM ten hagen
laboratory of experimental surgical 
Oncology, section of surgical Oncology, 
Department of surgery, erasmus 
Medical center, PO Box 2040, 3000 ca 
rotterdam, the Netherlands
Tel +31 10 704 3682
Fax +31 10 704 4746
email t.l.m.tenhagen@erasmusmc.nl 
Mahmoud reza Jaafari
Biotechnology research center, 
Pharmaceutical Technology Institute, 
Mashhad University of Medical sciences, 
PO Box 91775, 1365 Mashhad, Iran
Tel +98 513 180 1336
Fax +98 513 882 3251
email jafarimr@mums.ac.ir 
Journal name: International Journal of Nanomedicine
Article Designation: Original Research
Year: 2018
Volume: 13
Running head verso: Amin et al
Running head recto: Regulation of in vivo behavior of TAT-modified liposomes
DOI: 170274
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
5.
87
.2
36
 o
n 
04
-J
an
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
7442
amin et al
PEGylated nano-sized particles like Caelyx present a 
stealthy behavior, and therefore are not recognized by the 
reticuloendothelial system (RES), and circulate long in blood. 
It is believed that liposomes extravasate into tumor tissue 
through the leaky tumor vasculatures and retain there because 
of the impaired lymphatic drainage in tumors, a phenomenon 
known as the enhanced permeation and retention (EPR) 
effect.6 However, the PEGylated nature and rigid lipid com-
position of Caelyx dramatically decrease direct interaction 
with tumor cells, and doxorubicin (DXR) delivery to tumor 
cells mainly relies on DXR release from destabilized lipo-
somes which in turn is affected by phospholipases or acidic 
tumor environment.3,4 Therefore, ligand-modified liposomes 
have attracted attention to increase the intracellular delivery 
of liposomal drugs into tumor cells7 and reduce the retrograde 
movement of the extravasated liposomes back to the blood 
stream.8 However, this is an ideal scenario. Although active 
targeting dramatically enhances in vitro cellular delivery of 
liposomes, tremendous efforts on designing ligand-targeted 
liposomes against tumors resulted in no preclinical accepted 
preparation that progressed beyond Phase I or II of clinical 
trials.9 This shifted the scientific society’s concerns to ana-
lyzing the causes of these failures.7,10–12
It is well-recognized that once a nanoparticle (NP) enters 
the bloodstream, a layer of serum proteins named “protein 
corona” (PC) forms rapidly around the NP, which obscures 
the NP properties and confers a new identity to the NP surface. 
Afterward, it is the PC, rather than the pristine NP formulation, 
that governs the circulation fate and the biological response of 
the NP. Formation of opsonin-enriched PC fully explains the 
increased clearance rate of ligand-modified liposomes com-
pared to the non-targeted counterparts due to the RES function, 
which is now well known as great hurdle in passive delivery of 
targeted liposomes to tumor interstitium where these liposomes 
should actively deliver their payload into cells.7,9 Besides, the 
question arises on whether the surface-anchored ligand would 
be functional when a liposome is covered by a serum-derived 
PC. Formation of PC may, in part, be linked to failure of ligand-
targeted liposomes to emerge on the market,10 as a result of 
augmented clearance rate or loss of functionality.
TAT peptide derived from the transactivator of transcrip-
tion (TAT) of HIV-1 is a cell-penetrating peptide (CPP) 
that has drawn considerable attention to enhance cellular 
uptake of nanomedicines.14–17 The simplicity of sequence, 
ease, and low cost of preparation and conjugation, and 
most importantly, activity against a wide variety of cancer 
cells makes the TAT peptide a great candidate for ligand 
modification of liposomes.18,19 The exact mechanisms of 
cellular uptake, intracellular trafficking, and role of cell 
surface molecules in the internalization process of CPPs are 
still under debate.14,20,21 The electrostatic interaction of the 
positively charged TAT with negatively charged cell-surface 
glycoproteins was found to be a prerequisite for passage 
across the plasma membrane.22 However, proposed inter-
nalization pathways of TAT-modified cargoes into cells are 
controversial and both energy-independent translocation23 
or energy-dependent endocytosis24 were said to be involved 
in TAT regulated internalization. Although the capability of 
TAT-modified liposomes in association and internalization 
into tumor cells has been extensively studied in vitro,25–28 
in vivo therapeutic efficacy and biodistribution properties 
have not been clearly addressed in literature.
The positively charged TAT peptide may make liposomes 
prone to RES-mediated clearance. To avoid or mitigate 
this, optimizing ligand density on liposomes is the primary 
approach with respect to optimizing the efficacy and phar-
maceutical manufacturing.
The current study was conducted to delineate the biologi-
cal fate and activity of TAT-modified liposomes with respect 
to formulation optimization, stability, in vitro and in vivo 
drug delivery capacity and efficacy.
Materials and methods
Materials
Hydrogenated soya phosphatidylcholine (HSPC) and meth-
oxypolyethyleneglycol (MW 2000)-distearylphosphati-
dylethanolamine (mPEG2000-DSPE) were purchased from 
Lipoid (Ludwigshafen, Germany), maleimide-PEG2000 
distearoylphosphatidylethanolamine (Mal-PEG2000-DSPE) 
was purchased from Avanti Polar Lipids (Alabaster, AL, 
USA). 3,3′-Dioctadecyloxacarbocyanine perchlorate (DiO), 
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine, 
and 4-chlorobenzenesulfonate salt (DiD) were purchased 
from Thermo Fisher Scientific (Waltham, MA, USA). 
Ammonium sulfate, cholesterol, α-tocopherol, XTT, PMS 
and DXR hydrochloride were purchased from Sigma-Aldrich 
Co. (St Louis, MO, USA). TAT peptide analog equipped 
with 3G as spacer and a C for conjugation (CGGG-RK-
KRRQRRRGYG) was synthesized by Peptron Inc. (Daejeon, 
South Korea) with purity of 98%. Commercially available 
Caelyx was purchased from pharmacy. All other solvents 
and reagents were used as chemical grade.
Preparation of TAT-modified liposomes
Fluorescent-labeled PEGylated liposomes (FPLs) composed 
of HSPC, mPEG2000-DSPE, cholesterol, α-tocopherol, 
and the lipophilic dye (56.1:5.5:38.2:0.1:0.1 mol%) was 
prepared by solvent evaporation and hydration in HEPES 
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10 mM and NaCl 135 mM (pH 7.4), then downsized by 
10 minutes bath sonication and extrusion through polycar-
bonate membranes of 200 and 80 nm sequentially, using 
LIPEX™ (Northern lipid Inc., Vancouver, BC, Canada).
For post-insertion of the ligand, the conjugated DSPE-
PEG2000-TAT (for conjugation details see supplementary 
material and Figure S1) was first dispersed in distilled water 
at a concentration of 840 nmol/mL followed by 10 minutes 
agitation to form micellar lipopeptide. Considering that 
liposomes of 100 nm size are composed of 80,000 phos-
pholipid molecules, the amounts of liposomes and micellar 
DSPE-PEG2000-TAT were adjusted to prepare liposomes 
with different surface densities of TAT (Table S1). A cal-
culated amount of micellar lipopeptide was then added to 
preformed FPL (FPL-TATs) or Caelyx (PLD-TATs) in a 
glass tube under argon atmosphere and incubated at 50°C 
for 30 minutes with gentle agitation.
characterization and stability 
assessments of liposomes
Liposomes were characterized with respect to size, polydis-
persity index, and ζ-potential by a dynamic light scattering 
instrument (Nano-ZS; Malvern Instruments, Malvern, UK) 
at 25°C with a scattering angle of 173°. The phospholipid 
content of preparations was measured by a method based on 
Bartlett phosphate assay.29 Leakage stability of PLDs was 
assessed either through post-insertion treatment or during 
48 hours of incubation at 37°C in the presence of 30% fetal 
calf serum (FCS) (Supplementary material).
evaluation of in vitro behavior 
of TAT-modified liposomes
Flow cytometry analysis
The capability of TAT-modified liposomes in interaction 
with C26 (Cell Line Services GmbH, Eppelheim, Germany) 
and B16F0 (Sigma-Aldrich Co.) cells was evaluated by flow 
cytometry using FACS Caliber (BD Biosciences, San Jose, 
CA, USA). Briefly, 105 cells were seeded in 24-well plates 
and incubated overnight at culturing condition (Supplementary 
material). Then, the medium was replaced by liposomal prepara-
tions diluted in complete culture medium (100 nmol liposomal 
phospholipid/0.5 mL) and incubated for 3 hours at either 37°C 
or 4°C. Cells were then detached by trypsinization and washed 
three times with PBS (pH 7.4) containing 1% FCS. Five hun-
dred microliters of cell suspensions was incubated with 5 µL 
of propidium iodide (PI) (100 µg/mL) for 15 minutes at room 
temperature. Ten thousand cells gated on live cells by forward 
and side scatters ( FSC/SSC) and PI exclusion and assayed for 
the intensity of green DiO fluorescent dye.
confocal imaging
Internalization of FPL-TAT200 and DiO-labeled PLD-
TAT200 (Supplementary material) into tumor cells was also 
visualized using living cell confocal microscopy. Briefly, 
cells were seeded in cell culture chambers equipped with a 
fibronectin coated cover glass insert. After overnight incuba-
tion, cells were exposed to 100 nmol liposomal phospholipid 
(0.5 mL) for 3 hours at 37°C, washed with pre-warmed 
complete medium, and were analyzed on a Zeiss LSM 510 
META confocal laser scanning microscope.
The internalization pathway of FPL-TAT200 into 
C26 cells was also tracked in cells pre-incubated with 
Lysotracker® Red (Thermo Fisher Scientific (Waltham, 
MA, USA), a dye that specifically stains the acidified cell 
organelles.
cytotoxicity of PlDs against tumor cells
The antiproliferative effects of PLDs as well as free DXR 
were assessed using XTT assay. C26 and B16F0 cells 
were seeded at the density of 2,500 cells/well in 96-well 
microplates, incubated overnight at 37°C, and exposed to 
serially diluted liposomal DXR for 3 hours. Cells were 
then washed three times with pre-warmed complete culture 
medium and allowed to proliferate at 37°C for 72 hours 
in their complete culture medium. Finally, the culture 
medium was replaced with 100 µL of XTT (1 mg/mL)/
PMS (7.66 µg/mL) solution freshly prepared in phenol red 
and serum free culture medium. After 1 hour of incubation 
at 37°C in a CO
2
 incubator, the absorbance at 490 nm was 
recorded and the relative cell death (R) was calculated as 
follows: R=1-[(A
test
 - A
blank
)/(A
control
 - A
blank
)], where A
test
 and 
A
control
 were the absorbances of the cells treated with the test 
solutions and the culture medium (negative control), respec-
tively. A
blank
 was the absorbance of XTT/PMS solution added 
in cell free wells. IC
50
 values were then calculated based on 
dose–response curve using CalcuSyn version 2 software 
(Biosoft, Cambridge, UK).
evaluation of in vivo behavior 
of TAT-modified liposomes
Mice model of subcutaneous c26 colon carcinoma 
tumor model
This animal experiments were approved by the Institutional 
Ethical Committee and Research Advisory Committee of 
Mashhad University of Medical Sciences (research project 
code 913286). Female BALB/c mice aged 4–6 weeks were 
inoculated by a subcutaneous injection of 3×105 C26 colon 
carcinoma cells in the right flank. Animals with proper 
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tumor, as specified later, were used for therapeutic efficacy 
and biodistribution studies.
Dorsal skin-fold window chamber model 
of B16 melanoma
Animal experiments were approved by the Instantie voor 
Dierenwelzijn Erasmus Medical Center and conducted with 
permissions granted by the Nederlandse Dierexperimenten-
commissie. The experiments were performed according to 
the European Directive 2010/63/EU on the protection of 
animals used for scientific purposes. Ten million B16 cells 
were injected subcutaneously into the flanks of C57Bl6 
mice; the animals were housed at 20°C–22°C with a 
humidity of 50%–60%. Bulk tumors of 10 mm in diameter 
were used for transplantation into C57Bl6 mice, express-
ing an eNos-tag-GFP fusion protein constitutively in their 
vascular endothelium. Tumor pieces were implanted in a 
dorsal skin flap window chamber for intravital imaging.30–32 
Window chamber-bearing mice were used for experiments 
after 8–12 days of tumor implantation when the tumor size 
reached 4–6 mm in diameter. These mice were housed in an 
incubator room with a humidity of 70% and temperature of 
30°C–32°C.
Biodistribution of PlDs in mice model of c26 tumor
Biodistribution of PLD-TATs was evaluated in two doses 
of 10 and 15 mg/kg liposomal DXR, in two separate 
experiments. On day 14 post-tumoring, when the tumor size 
was ~5 mm wide, mice (eight per group) received liposomal 
DXR via the tail vein. Blood was collected via the orbital 
sinus 6 (four of eight mice) and 12 (other four mice) hours 
after dosing. At 24- or 48-hour time points, mice (four mice) 
were deeply anesthetized by ketamine-xylazine cocktail 
and euthanized. Blood was collected by heart puncture, and 
the tumor, kidneys, spleen, lungs, and liver were dissected, 
weighed, and less than 300 mg of tissues were transferred 
into 2 mL polypropylene microvials (Biospec Products, 
Bartlesville, OK, USA) containing 1 mL of acidified alcohol 
(90% isopropanol/0.075 M HCl) and zirconia beads and 
homogenized by Mini-Beadbeater-1 (Biospec Products). 
Blood was allowed to coagulate at 4°C and then centrifuged 
to separate the serum. Sera were separated by centrifuging 
at 14,000× g for 10 minutes33 for mice receiving 10 mg/kg 
and at 5,000× g for 5 minutes for mice receiving 15 mg/kg 
of liposomal DXR. Then an adequate amount of serum was 
diluted in 1 mL of acidified isopropanol. To extract DXR, 
homogenized tissue samples and sera were stored at 4°C 
overnight. Finally, all samples were centrifuged to collect the 
supernatant for DXR assay using spectrofluorimetric method 
(excitation: 470 nm, emission: 590 nm). The calibration 
curves were obtained by preparing serial dilutions of DXR 
in tissue and sera extracts of control mice.
Therapeutic efficacy of PLDs against subcutaneous 
c26 tumor model
On day 7 post-inoculation, mice with palpable tumor received 
a single tail vein injection of either sucrose 10% solution as 
negative control or DXR at 10 or 15 mg/kg encapsulated in 
PLDs. The tumor volume was estimated by measuring the 
three orthogonal diameters of tumors using the (a×b×c)/2 for-
mula. Mice were monitored for up to 60 days post-inoculation 
or until one of the following conditions for euthanasia was 
met: 1) their body weight dropped below 20% of their initial 
mass; 2) their tumor was greater than 2.0 cm across in any 
dimension or the tumor volume was greater than 1 cm3; 
3) they became lethargic or sick and unable to feed; or 4) they 
were found dead.33,34
In vivo visualization of intratumoral behavior 
of TAT-modified liposomes
In vivo behavior of fluorescently labeled TAT-modified lipo-
somes (FPL-TAT-200) in tumor was observed by intravital con-
focal microscopy on dorsal skin-fold window chamber-bearing 
mice after an iv injection through tail vein at a dose of 5 µmol of 
lipid. The mice were then anesthetized with isoflurane (Nicholas 
Piramal, London, UK) and placed on a heated stage (37°C) 
under the confocal microscope (Zeiss LSM 510 META).
Impact of mice serum on colloidal properties 
of PlD-TaTs
Mimicking in vivo serum/PLD ratio after an iv injection of 
15 mg/kg liposomal DXR, 160 µL of different combinations 
of PLD-TATs were diluted in 1,200 µL of normal mice 
serum (Abcam, Cambridge, UK) and incubated at 37°C for 
6 hours.
To assess the impact of serum on colloidal proper-
ties of PLD-TATs, 100 µL of serum-treated or untreated 
PLD-TATs were diluted in 1,900 µL of Tris-HCl 10 mM 
and NaCl 135 mM (pH 7.4), and the size, ζ-potential, and 
polydispersity index (PDI) were measured by the dynamic 
light scattering instrument.
sDs-Page analyses of serum-treated liposomes
Liposomes incubated with mouse serum were passed 
through Sepharose CL-4B (Pharmacia, Uppsala, Sweden) 
size-exclusion column (24×2.5 cm) equilibrated with 
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Tris-buffered saline at pH 7.435 to separate liposomes from bulk 
serum protein. Column-recovered liposomes were collected, 
concentrate by freeze drying, and resuspended in distilled 
water. DXR concentration was assayed and equal amount of 
liposomal DXR in adjusted volume of 25 µL was diluted with 
25 µL of 2× Laemmli sample buffer (Bio-Rad) supplemented 
with 5% mercaptoethanol (Sigma-Aldrich Co.) and heated in 
a thermal shaker for 10 minutes at 99°C. Fifty microliters of 
samples was then applied on precast 4%–20% gradient Mini-
Protean TGX gel (Bio-Rad). The electrophoresis buffer was 
composed of 25 mM Tris, 192 mM glycine, and 0.1% SDS 
(pH 8.3). After electrophoresis, the gel was silver-stained with 
SilverQuest staining kit (Thermo Fisher Scientific).
statistical analysis
Statistical analyses were performed using GraphPad Prism 
version 6 (GraphPad Software, Inc., La Jolla, CA, USA). 
Survival data were analyzed by the log-rank test. For other 
comparisons, one-way ANOVA and Newman–Keuls mul-
tiple comparisons test were employed.
Results and discussion
characterization of liposomes
The particle size of various liposomes was around 100 nm 
(PDI ,0.1). While TAT had no impact on the observed 
liposome size, its presence on liposome surface reduced 
the negative ζ-potential of liposomes (Tables S1and S2). 
Importantly, insertion of TAT at elevated temperature caused 
no significant DXR release (Figure 1 inset). Liposomes 
were also stable in the presence of serum proteins and no 
pronounced leakage or instability was found when liposomes 
were incubated with FCS (Figure 1).
In vitro assessment of intracellular 
fate of TaT liposomes
In vitro association of TAT-modified liposomes with cells 
including C26 and B16 revealed an increased liposome–cell 
association by increasing the TAT density with identical 
pattern at both 4°C and 37°C (Figures 2A and S2). While 
plain liposomes were barely observable associated with cells 
(Figure S3), TAT was effective in improving liposome–cell 
association even at a density of 25 moieties per liposome, 
which in turn resulted in elevated cytotoxicity of PLD-TATs 
(Figure 2B). Insertion of 25, 50, 100, 200, 300 or 400 TAT 
peptides on Caelyx increased the cytotoxicity of Caelyx by 2, 
6.1, 14.1, 26.4, 35.8, and 49.6 fold against C26 cells, respec-
tively, and by 1.7, 3.8, 7.8, 16.6, 21.3, and 33 fold against 
B16 cells, respectively. However, the enhanced association 
or cytotoxicity did not follow a linear correlation indicat-
ing saturation. Flow cytometry and cytotoxicity analysis 
revealed the following trends. The densities of 0–100 TAT 
peptides/liposome produced a sharp increase in associa-
tion (Figure 2A) and cytotoxicity (Figure 2B), whereas for 
densities of 100–400 TAT peptides/liposome, the increased 
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Regulation of in vivo behavior of TAT-modified liposomes
association or cytotoxicity was diminished. Based on these 
data, densities above 200 TAT peptides/liposome were 
excluded from further in vivo experiments.
Analyzed by ZEN 2012 SP2 blue edition (Carl Zeiss 
Microscopy GmbH), co-localization of green DiO lipo-
somal dye with the red fluorescence of acidified endosomal 
compartments labeled with LysoTracker®Red (Figure 2C) 
indicated that TAT enabled liposomes to be internalized 
into C26 via receptor-mediated endocytosis. Internaliza-
tion of TAT liposomes into B16 cells was also found to be 
mediated by endocytosis (Figure S2C). Alternatively, no 
free TAT-modified liposome was detected in cell cytoplasm, 
indicating the absence of direct translocation of TAT lipo-
somes into cells.
To analyze the intracellular fate of PLD-TATs, DiO-
labeled PLD-TAT200 was prepared and its intracellular 
fate was monitored over 36 hours (Figure 2D–I) in C26 
cultured cells. TAT remarkably enhanced the internaliza-
tion of PLD into cells (Figure S3I and J). However, the 
most significant observation in this experiment was the 
delayed nuclear delivery of DXR by PLD-TAT200 com-
pared to free DXR. While free DXR promptly reached the 
cell nucleus (Figure 2J), no significant amount of DXR 
could be detected along the lines crossing the nucleus of the 
cells incubated with PLD-TAT and imaged between 3 and 
7 hours post-incubation (Figure 2D–G) as liposomal DXR 
was mainly entrapped in the endosomal system. At 12 hours 
post-exposure, minor nuclear delivery of DXR could be 
detected, while significant levels of DXR staining was only 
detected in the nucleus 24–36 hours later (Figure 2H and I), 
which probably resulted from slow DXR release from the 
endosomal system (Figure S2H and I). Comparable delayed 
nuclear delivery was also observed with a density of 
400 peptides (Figure S4 and supplementary video). These 
results on the one hand indicate that TAT does not regulate 
liposome–cell fusion or endosomal escape, and on the other 
hand reveal that, although TAT dramatically promotes PLD 
internalization into cells, it does not affect intracellular 
availability. We observed that internalized liposomes were 
mainly retained in lysosomes and only provided a source 
of slow-release DXR, which was found to be effective in 
killing the cells (Figure 2B).
In fact, this delayed release is attributed to the high con-
centration of intraliposomal DXR sulfate (.200 mM). DXR 
molecules tend to form aggregates and a visible precipita-
tion of DXR sulfate occurs at a concentration of ,2 mM.36 
Therefore, at least 100-fold dilution is required for DXR 
monomers to occur and escape the lysosome and reach the 
nucleus. Besides, the acidic pH of lysosomes further reduces 
the dissolution rate of DXR.
Biodistribution
Biodistribution of PLD-TATs as well as Caelyx was exten-
sively evaluated at doses of 10 and 15 mg/kg in mice bearing 
C26 tumor, in two separate experiments with minor modifica-
tion in the protocol involving the separation of sera.
In the first experiment, in which mice received 10 mg/kg 
liposomal DXR and sera were separated by 14,000× g cen-
trifugation, it was observed that the plasma clearance rate of 
liposomes increased gradually with increased TAT density 
(Figure 3A). However, all preparations created statistically 
identical levels in liver, spleen, lungs, and kidneys (Figure 3B 
and C) and accumulated to the same extent inside the tumor 
(Figure 3D) 48 hours post-injection (P.0.05). Based on 
our previous observations,13,32 it was first speculated that 
reduction of plasma DXR levels should be attributed to fast 
clearance of the RES by cells, directed against PLD-TATs 
because of the cationic charge of TAT molecules. This should 
have been reflected in higher levels of DXR in spleen and 
liver of mice that received short circulating liposomes.13.32 
Yet, analysis of DXR levels in liver and spleen revealed no 
significant differences in uptake of TAT-modified and non-
modified PLDs by these two organs, which argue against a 
dominant function of the RES against PLD-TATs. On the 
other hand, PLD-TATs showed no leakage instability in bio-
logical fluid in vitro (Figure 1), and DXR levels in kidneys 
of different groups were statistically identical which reject 
the hypothesis that liposomes become more unstable and 
release DXR during circulation, as well. Besides, identical 
DXR levels in lungs of mice receiving these preparations 
indicate no aggregation upon administration. Interestingly, 
despite the rapid drop in serum DXR levels of mice receiv-
ing PLD-TATs, tumor accumulation of different PLDs was 
identical and the apparent differences in plasma clearance 
rates of different PLDs did not impact on their extravasation 
and tumor accumulation.
We were doubtful as to whether 14,000× g centrifugation 
is sufficient for serum separation; therefore, in the second 
experiment, in which mice received 15 mg/kg liposomal 
DXR, sera were separated with a lower centrifugation force 
of 5,000× g. In contrast to the first experiment, no signifi-
cant differences were found in plasma levels of PLD-TATs 
and Caelyx (Figure 3E). Consistent with the first experi-
ment, DXR concentration in liver, spleen, lungs, kidneys 
(Figure 3F–H), and tumor (Figure 3I) showed virtually 
similar values for all preparations (P.0.05).
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It was also possible that equal levels in liver and spleen 
at 48 or 24 hours after administration could be attributed to 
the metabolizing function of these two organs. However, 
at 6 hours post-injection, DXR levels in spleens of mice 
receiving Plain-PLD or PLD-TATs were identical, and a 
slight increase in hepatic levels of DXR in mice receiving 
PLD-TATs (Figure S5) could not justify the observed rapid 
clearance rate of first experiment (Figure 3A).
It is worth mentioning that once the mice received 15 mg/kg 
DXR as PLD-TATs and sera were separated by the high 
centrifugation force (Figure S6), the correlation between 
serum DXR level and TAT density was identical, as shown 
in Figure 3A. Based on the above-mentioned results, we 
concluded that the different pattern of serum DXR observed 
in the current experiments is not attributed to dosing.
Taken together, we hypothesize that the reduced plasma 
levels observed in the first experiment must be attributed 
to the centrifugation forces. To confirm this finding, PLD-
TATs were subjected to centrifugation at both 14,000× g for 
10 minutes and 4,000× g for 5 minutes. Since none of the 
PLD-TATs sedimented by these forces (data not shown), 
we hypothesized that protein binding on PLD-TATs during 
circulation might have increased PLD-TATs density which, 
in turn, caused sedimentation by high centrifugal forces. This 
prompted us to investigate the protein binding of PLD-TATs 
in the presence of mouse serum, which is presented in the 
following section.
Impact of mice serum on colloidal 
properties of TAT-modified liposomes
PLD-TAT-25, 100, 200, 400, and Caelyx were incubated with 
freshly prepared mouse serum for 6 hours at 37°C and were 
then compared against untreated counterpart with respect to 
their colloidal properties and protein binding.
Figure 3 Biodistribution of PLDs at different time points after a single IV injection of 10 mg/kg (A–D) or 15 mg/kg (E–I) liposomal DXR in different organs including serum 
(A, E), spleen and liver (B, F, and G), lungs and kidneys (C, H), and tumor (D, I) in BALB/c mice bearing C26 tumor. Data represent mean ± SE (n=4).
Abbreviations: TAT, transactivator of transcription; PLD, PEGylated liposomal doxorubicin; DXR, doxorubicin.
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Regulation of in vivo behavior of TAT-modified liposomes
Analysis of colloidal properties of PLDs before and 
after serum treatment (Figures 4A, B) (Figure S7) revealed 
a reduction in mean diameter of Caelyx after serum treat-
ment. This was consistent with others studies investigating 
PC formation on liposomes37–39 that have related this to an 
osmotically-driven shrinkage due to high elastic deforma-
tion of liposomes. While in bare liposomes, incorporation of 
TAT did not cause significant size changes (P.0.05), serum-
treated PLD-TATs revealed a direct correlation between 
their size and their TAT density, indicating the thickness of 
the PC increased with increasing TAT moieties on liposome 
surface (P,0.05). Nonetheless, all serum-treated PLDs 
showed unimodal size distribution without serious aggrega-
tion (Figure S7). Interestingly, while the positive charge of 
TAT reduced the negative charge of PLDs, formation of PC 
normalized their ζ-potentials as all serum-treated PLDs had 
similar ζ-potential values (P.0.05). Evidently, serum tries 
to neutralize the TAT moieties by increasing the number of 
macromolecules adsorbed on liposomes; the more TAT is 
inserted, the thicker PC is formed.
The increased thickness of PC as a function of TAT 
density also reflected in enhanced sedimentation at high 
centrifuge force of 14,000× g proportional to TAT density, 
ie, Caelyx , PLD-TAT-25 , PLD-TAT-100 , PLD-TAT-
200. However, 5,000× g centrifugation caused no notable 
sedimentation. Although the magnitude of differences in in 
tubo condition was not as large as what was observed in vivo, 
these data were consistent with the biodistribution results, 
demonstrating the impact of serum-derived components on 
sedimentation of PLD-TATs during serum separation.
Liposomes recovered from serum were also run on 
SDS-PAGE. As could be seen in Figure 4C, while all serum-
treated PLDs indicated identical band patterns, the intensity 
of the bands, especially between 50 and 75 kD, was directly 
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Figure 4 Impact of mouse serum on colloidal properties of PLD-TATs including size (A) and ζ-potential (B) after 6 hours of incubation with mouse serum at 37°C, and (C) 
sDs-Page analysis of serum-derived proteins associated with liposomes.
Notes: Data are represented as mean ± SD of at least four (n=4) different measurements carried out for each sample in Tris-HCl 10 mM, NaCl 135 mM, pH 7.4 (these 
results also tabulated in Table s2). Panel C represents the SDS-PAGE analysis of serum-derived proteins bound to 1: PLD (Caelyx), 2: PLD-TAT-100, and 3: PLD-TAT-200. 
liposomes were incubated with mouse serum for 6 hours at 37°c, separated by sepharose cl-4B column, and layered on top of the gel bed and elution was started at 
room temperature.
Abbreviations: TaT, transactivator of transcription; PlD, Pegylated liposomal doxorubicin.
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proportional to TAT density on PLDs. SDS-PAGE results 
were consistent with the results obtained by size distribu-
tion analysis where thickness of PC increased by increasing 
surface-anchored TAT, while no massive protein binding 
and aggregation had taken place upon exposure of liposomes 
with serum (Figure S7 and Table S2).
Judging from the main different SDS-PAGE band 
(between 50 and 75 kD) and the direct correlation of the band 
intensity with TAT density (Figure 4C), we concluded that 
the presence of TAT moieties on PLD surface is associated 
with TAT-dependent adsorption of proteins that represent 
band of molecular weight around 65 kD. With regard to the 
biodistribution properties of PLD-TATs, eg, the stealth-like 
behavior during circulation, it is most likely that surface 
association of these proteins on PLD-TATs shields TAT 
residues from RES function by inhibiting opsonins adsorp-
tion on particle surface.10,40
While our findings indicate that albumin (MW 67 kD)41 
is involved in dysopsonization of PLD-TATs,10,41,42 thorough 
identification and comparison of PC associated with PLD-
TAT vs PLD-Plain is needed. To this end, liquid chroma-
tography mass spectrometry-based proteomics analysis is 
in process.
Visualization of tumor cell association 
of TAT-modified liposomes in vivo
In vivo behavior of fluorescently labeled TAT-modified 
liposomes (FPL-TAT-200) in tumor was observed by 
intravital confocal microscopy on dorsal skin-fold window 
chamber-bearing mice after iv injection at a dose of 5 µmol 
of lipid. As can be seen in Figure 5A–F, TAT-modified lipo-
somes strongly associated with tumor cells after extravasation 
into tumor as early as 12 hours post-injection and at later 
time points either in regions with established tumor vessels 
Figure 5 Intravital microscopy imaging of the behavior of DiD-labeled (purple), TAT-modified (A–F), or DiD-labeled plain liposomes (G, H) inside B16F0 tumors using the 
dorsal skin-fold chamber. Mice were injected with 5 µmol of lipid. TAT-modified liposomes were found to be associated with tumor cells after extravasation at different time 
points, while plain liposomes hardly bound to tumor cells.
Abbreviations: TAT, transactivator of transcription; DiD, 4-chlorobenzenesulfonate salt; GFP, green fluorescent protein.
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(Figure 5A, C, and E) or the growing front (Figure 5B, D, 
and F). Meanwhile, plain liposomes (Figure 5G and H) 
showed minor association with cells and diffusely distributed 
inside tumor. Intravital imaging also shows the limited move-
ment of FPL-TAT from the extravasation site. This is more 
clear in the tumor growing fronts (5A, D, and F) in which 
extravasated liposomes vastly interact with cells surrounding 
neovasculatures while no detectable liposome–cell associa-
tion was observable in non-vascularized regions. Figure 5C 
and F also revealed the prolonged circulation time of FPL-
TAT as it was observable inside tumor vasculature 24 and 
48 hours post-injection, respectively. This brings the ques-
tion of how the protein coated PLD-TATs were capable of 
interacting with tumor cells inside the tumor interstitium. 
Although serum treatment of FPLs reduced the extent of 
liposome–cell association in static condition (Figure S8), 
interaction of serum treated and non-treated FPL-TATs 
was blocked equally in the presence of heparin (Figure S9) 
and cells starved of serum did not uptake PC-associated 
liposomes more than what normal cells did in spite of their 
higher demand on serum nutrients (Figure S10). These results 
reveal that association of TAT liposomes is only mediated by 
the exposing TAT residues and PC only reduces the exposure 
rate of TAT peptide rather than blocking it.
Hadjidemetriou et al38,39 showed an incomplete formation 
of PC around PEGylated liposomes modified with IgG ligand 
which obviously justifies the interaction of PLD-TAT with 
tumor cells. However, given the fact that PC formation is a 
thermodynamic response of blood pool for diminution of the 
Gibbs free energy and compensation of the high free energy 
protruded by NP surface, the heterogeneous formation of PC 
seems not convincing. Whereas, it is more likely that regions 
observed intact were artifacts created during extensive wash-
ing steps or sample preparation for electron microscopy imag-
ing. Considering the ability of PC-associated TAT liposomes 
in interacting with cells in static conditions of in vitro experi-
ments (Figures S8 and S10) or in vivo tumor interstitium and 
that they were not recognized by RES in dynamic conditions 
of circulation, we concluded that differences in evolution of 
PC in static vs dynamic conditions determine the targeting 
ability of TAT-modified liposomes.
In fact, composition, thickness, and decoration of PC is 
dependent on a variety of factors including physicochemical 
properties of NP surface (surface chemistry, size, charge, 
shape, topography, and curvature) and environmental fac-
tors such as protein source and incubation protocol.43,44 
Pozzi et al45 demonstrated that even in in vitro conditions, 
the composition of PC formed under static conditions is 
different from what is formed under dynamic conditions. 
In addition, the PC is initially composed of proteins with 
high concentration and high association rate constant that, 
depending on the surface characteristics, may then dissociate 
to be replaced by other proteins with lower concentration, 
lower exchange rate, and higher affinity.46,47 These exchange 
processes are important when particles redistribute from one 
compartment or organ to another. For instance, as speculated 
earlier, albumin could be one of the potential dysopsonizing 
candidates. At physiological pH, the difference between the 
negative charge of albumin (–19) and the positive charge of 
TAT (+8) enforces albumin–TAT binding. However, low-
ering the pH from 7.4 to 6 reduces the negative charge of 
albumin to -6,48 whereas basic TAT (pI TAT: 12.13) does 
not undergo significant charge changes in this pH range. 
Theoretically, it is likely that reduced pH of the tumor inter-
stitium49 loosens the electrostatic interaction between albumin 
and TAT and allows albumin to be dissociated by proteases 
or through competitive interactions with tumor-associated 
stromal matrix such as secreted protein acidic rich in cysteine 
(SPARC), a prototypic matricellular protein expressed around 
many cancer cells50,51 which particularly has high affinity to 
albumin molecule,52–54 making TAT residues accessible and 
functional in the proximity of tumor cells.
Therapeutic efficacy
Antitumor efficacy of different PLDs was evaluated in an sc 
murine C26 colon carcinoma tumor model after a single dose 
of either 10 or 15 mg/kg liposomal DXR. Tumor growth rates 
and survival results are depicted in Figure 6. Median survival 
time (MST), time to reach end point (TTE), and % tumor 
growth delay (TGD) for each treatment group are also sum-
marized in Table 1. When mice received 10 mg/kg liposomal 
DXR, no significant differences were observed amongst 
different treatments (Table 1). However, administration of 
PLD-TAT-100 indicated a superior antitumor trend com-
pared to other treatments and cured one mouse by complete 
elimination of the tumor (Figure 6A) and resulted in a slower 
tumor growth rate (Figure 6B).
Treatment with 15 mg/kg liposomal DXR magnified the 
differences between the treated groups. While modification 
of Caelyx with 25 or 50 TAT lipopeptides did not enhance 
the therapeutic efficacy of Caelyx, PLD-TAT-100 showed 
a superior antitumor effect and caused the longest MST, 
TTE, and the highest %TGD. Forty percent of mice treated 
with this preparation were cured (Figure 6D), and this group 
exhibited a slower tumor growth rate (Figure 6E). In con-
trast, PLD-TAT-200 exhibited significantly (P,0.05) lower 
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Table 1 Therapeutic efficacy data of TAT-modified and non-modified PLDs in mice bearing C26 tumor in doses of 10 and 15 mg/kg 
liposomal DXR
Dosing 10 mg/kg 15 mg/kg
MST
(days)
TTE (days ± SE)
(n=7)
TGD
(%)
MST
(days)
TTE (days ± SE)
(n=5)
TGD
(%)
caelyx® 34 32.15±7.93 42.51 56 65.25±11.82 164.71
PlD-TaT-25 34 33.99±2.64 50.65 48 48.07±4.47 95.00
PlD-TaT-50 38 33.57±1.42 48.78 44 58.28±12.44 136.41
PlD-TaT-100 38 40.01±8.47 77.29 64 80.94±15.02 228.35
PlD-TaT-200 28 28.70±2.24 27.23 44 43.85±4.23 77.88
Sucrose 10% 24 22.56±0.77 – 25 24.65±0.73 –
Abbreviations: TAT, transactivator of transcription; PLD, PEGylated liposomal doxorubicin; DXR, doxorubicin; TTE, time to reach end point; SE, standard error; 
TgD, tumor growth delay; MsT, median survival time.
therapeutic values (Table 1) and significantly faster tumor 
growth rate compared to PLD-TAT-100 (Figure 6E).
In contrast to the in vitro toxicity of PLD-TATs, where 
increasing the TAT density directly resulted in increased tox-
icity against tumor cells, this trend was not observed in vivo. 
While all PLD-TATs indicated comparable tumor accumula-
tion, PLD-TAT-100 was the most effective preparation and 
PLD-TAT-200 was repeatedly found to be the least effective 
preparation at both dosages.
As visualized in Figure 5, while FPL-TAT shows 
homogenous interaction with cells around established 
tumor vessels (Figure 5A, C and E) – representing tumor 
periphery where tumor vessels are distributed in high density 
– in growing fronts (Figure 5B, D, and F), interaction of 
Figure 6 In vivo therapeutic efficacy of various liposomal preparations in female BALB/c mice bearing C26 colon carcinoma tumor after iv administration of a single dose of 
either 10 mg/kg (panels A–C) or 15 mg/kg (panels D–F) liposomal doxorubicin or sucrose 10% on day 7 after tumor inoculation. A and D represent tumor growth rates, 
B and E represent survival curves, and C and F represent animal weight changes followed by injection. Data depicted as mean ± SE (n10 mg/kg=7, n15 mg/kg=5).
Abbreviations: TaT, transactivator of transcription; PlD, Pegylated liposomal doxorubicin.
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Regulation of in vivo behavior of TAT-modified liposomes
extravasated FPL-TAT is greatly restricted to tumor cells 
located close to vessels. Limited associations could be seen 
in dark regions of central tumor mass where no vasculature 
is present.
In fact, extravasation of NPs from functional blood ves-
sels in central region of tumor, if there is any, is negligible 
due to high interstitial fluid pressure,55 and tumor accumu-
lation of NPs mainly relies on peripheral extravasation.56–58 
Therefore, penetration of NPs from tumor periphery into 
deeper tumor regions is crucial to effectively eliminating 
cancer cells. The lack of convective movement inside tumors 
restricts NP transport mainly to diffusion. However, intra-
tumoral diffusion of NPs is strongly hindered by the dense 
complex structure of the extracellular matrix (ECM) in solid 
tumors.56,57 Moreover, specific affinity of macromolecules or 
NPs for tumor cells may further reduce the effective diffu-
sion rate of targeted liposomes inside tumor interstitium.55,59 
This is consistent with intravital imaging analysis where 
FPL-TAT movement from extravasate site was limited to 
surrounding cells. From this, it could be concluded that the 
antitumor activity of PLD-TAT200 is affected by its poor 
spatial distribution throughout the tumor as a function of its 
high avidity to tumor cells. In addition to this, PLD-TATs 
showed strong cell internalization but delayed DXR delivery, 
as they are mainly retained in lysosomal system for a long 
period of time (Figure 2). Therefore, due to a higher avidity, 
PLD-TAT-200 delivered a large amount of DXR to cells 
immediately surrounding blood vessels in peripheral tumor 
regions, leaving deep regions of the tumor untouched by the 
therapy. Another evidence that supports the indirect relation-
ship of avidity with the spatial distribution of PLD-TATs was 
the occurrence of skin necrosis when mice bearing dermal 
C26 tumor received different PLD-TATs (Supplementary 
material), where increasing the avidity of PLD-TATs by 
increasing TAT density was accompanied by an increase in 
the occurrence of skin necrosis (Figure S11 and Table S3). 
In dermal tumor, the dermis is tightly in contact with tumor 
periphery due to pressure derived from tumor growth. There-
fore, the poor spatial distribution of peripherally extravasated 
liposomes, due to liposome avidity, might have resulted in 
localization of sufficient levels of DXR to cause local cell 
kill and damage in the periphery of the tumor and adjacent 
skin which was reflected as necrosis in skin. These reveal that 
limited penetration depth, either as a result of dense ECM or 
NP avidity, plays more crucial role compared to EPR.
Another striking observation of the therapeutic efficacy of 
PLD-TATs was their safety, as we observed no remarkable 
systemic side effects. As represented in Figure 6C and F, 
post-injection monitoring of animal weights, which is an 
indicator of incidence of systemic side effects, revealed no 
difference between treatment with PLD-TATs and Caelyx. 
The safety of PLD-TATs may further underscore the crucial 
role of PC composition that, in this study, covered TAT moi-
eties from off-target interactions during circulation.
Taken together, our results indicate that insertion of 
100 TAT peptides on PLD provides a superior balance 
between intracellular drug delivery and tumor penetration 
compared to other preparations, thereby inflicting a better 
antitumor effect.
Conclusion
Herein we show a comprehensive investigation of the biologi-
cal performance of TAT-modified liposomes. TAT regulates 
cellular internalization of liposomes via endocytosis rather 
than direct translocation or fusion. PLDs modified with dif-
ferent densities of TAT peptide were found to be safe and 
long circulating. However, to gain a proper antitumor therapy, 
their avidity should be optimized to balance between cellular 
uptake and penetration depth into tumor. We observed an 
enhanced therapeutic efficacy of a commercial PLD, Caelyx, 
against C26 colon carcinoma when 100 TAT moieties were 
present. Since, PLD-TATs are easily prepared in house and 
impose no serious manufacturing complexity, further devel-
opment is warranted.
The current study, which to the best of our knowledge is 
the first report in literature, provides a vivid example showing 
the effect of PC formation on in vivo and in vitro behavior of 
TAT-modified liposomes. TAT moieties on liposomes seem 
to adsorb dysopsonins rather than opsonins, which results 
in protection of liposomes from clearance and off-target 
interaction during dynamic condition of circulation. Impor-
tantly, targeting ability of TAT-modified liposomes in static 
condition of the tumor interstitium was maintained in spite 
of the presence of PC. We conclude that formation of a PC 
on TAT liposomes did not obscure the targeting moiety for 
interaction with tumor cells. We speculate that the difference 
in kinetic on and off rates (or equilibrium binding constants) 
of PC components in static condition vs dynamic condition 
may regulate this behavior of TAT liposomes.
In contrast to the general consensus that ligand modifi-
cation does not necessarily improve tumor localization of 
liposomes as a result of enhanced clearance, some reports 
have shown an improved tumor accumulation due to active 
targeting. This important contradiction might be resolved by 
considering that PC formation balances between improved 
circulation time and better uptake by tumor cells.
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Finally, our observations highlight the need to take PC 
formation into account during preclinical evaluation of NPs, 
particularly ligand-modified NPs. Optimization of ligand 
density and performance of modified NPs should be thor-
oughly tested in vitro and in vivo to establish the optimally 
balanced product.
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